ICICI Direct has given Hold recommendation for Alembic Pharma with a target price of Rs. 1055 in its research report issued on May 05, 2021

ICICI Direct’s research report on Alembic Pharma

Q4 revenues grew 6.1% YoY to Rs 1280 crore with strong growth in RoW formulations and API segment being partly offset by 17.7% YoY decline in US sales to Rs 475 crore. Domestic formulations grew 4.7% YoY to Rs 358 crore. RoW sales grew a robust 76.5% YoY to Rs 233 crore whereas API segment grew 38.1% YoY to Rs 214 crore. EBITDA margins declined 45 bps YoY to 26.7% with lower gross margins being mostly offset by lower employee cost. EBITDA grew 4.3% YoY to Rs 342 crore. Adjusted PAT grew 6.5% YoY to Rs 251 crore.

Outlook

We maintain HOLD rating and arrive at a target price of Rs 1055 (unchanged) based on 20x FY23E EPS of Rs 52.7.

 

Leave a Reply

Your email address will not be published. Required fields are marked *